<DOC>
	<DOCNO>NCT01353638</DOCNO>
	<brief_summary>Peritoneal dialysis ( PD ) cost effective safe form renal replacement therapy patient suffer end stage renal disease . However currently available PDF ( peritoneal dialysis fluid ) biocompatible peritoneal cavity cell . Acute cytotoxic effect majority current glucose-based PDF cause low pH , lactate , high glucose degradation product ( GDP ) . Toxic effect PDF thus extend suppression mesothelial HSR ( heat shock reaction ) follow PDF exposure result increased susceptibility mesothelial cell PDF exposure : PDF inherent stress factor fail adequately induce HSP effector cellular stress response - adequate HRS rather seem block . Hence , therapeutic approach activate enhance HSR reduce peritoneal damage organ failure improve survival organism . Preclinical result demonstrate supplementation PDF pharmacological dos alanyl-glutamine restore HSP expression increase resistance mesothelial cell in-vitro model PD preserve peritoneal integrity in-vivo model PD . After positive preclinical result , study shall clarify , whether addition alanyl-glutamine commonly use glucose-based PDF safe tolerable . Therefore PDFs drain randomize cross-over study . Main outcomes measure total HSP expression peritoneal cell change peritoneal transport kinetics presence/absence/severity side effect .</brief_summary>
	<brief_title>Safety Efficacy Addition Alanyl-Glutamine-Dipeptide Dialysis Solution Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure Male female patient age â‰¥ 19 year old Chronic renal failure ; 2 month stable PD peritonitis within previous 2 month Without severe concomitant disease Negative pregnancy test female patient childbearing potential adequate contraception female patient childbearing age Known hypersensitivity study medication Treatment another investigational drug within 1 month prior start study medication Malignancy require chemotherapy radiation Pregnancy nursing , Presumed noncompliance Limited efficacy peritoneal dialysis due anatomical anomaly severe intraabdominal adhesion Clinical significant inflammatory parameter Less 50 kg body weight Immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Alanyl-Glutamine-Dipeptide</keyword>
	<keyword>Heat shock protein</keyword>
	<keyword>Peritoneal cell</keyword>
	<keyword>functional maintenance peritoneal membrane</keyword>
</DOC>